# CONMED Corporation (CNMD)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $1.09B  
**Price:** $34.87 (-3.94%)

> CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical equipment and medical devices for orthopedic and general surgery specialties. The company's orthopedic surgery segment provides products for soft tissue repair, powered resection instruments, and foot and ankle surgery systems. Its general surgery division offers advanced surgical and endoscopic technologies, including the AirSeal insufflation system for minimally invasive procedures, smoke evacuation products, electrosurgical generators, and specialized devices for gastroenterology and pulmonology procedures. CONMED serves healthcare professionals including surgeons and specialists in orthopedics, general surgery, gynecology, thoracic surgery, and related fields across approximately 100 countries. The company operates through sales subsidiaries and distribution networks in major markets including the United States, Europe, Asia Pacific, and other regions. CONMED caters to various healthcare settings ranging from ambulatory surgery centers and endoscopy suites to large hospital systems, focusing on delivering solutions that enhance surgical efficiency and patient outcomes in value-based care environments.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.37B | $750M | $103M | $47M | — |
| 2024 | $1.31B | $733M | $200M | $132M | — |
| 2023 | $1.24B | $676M | $121M | $64M | — |
| 2022 | $1.05B | $571M | $70M | -$81M | — |
| 2021 | $1.01B | $568M | $110M | $63M | — |
| 2020 | $862M | $460M | $46M | $10M | — |
| 2019 | $955M | $525M | $79M | $29M | — |
| 2018 | $860M | $469M | $71M | $41M | — |
| 2017 | $796M | $431M | $47M | $55M | — |
| 2016 | $764M | $408M | $38M | $15M | — |
| 2015 | $719M | $382M | $51M | $30M | — |
| 2014 | $740M | $404M | $53M | $32M | — |
| 2013 | $763M | $412M | $57M | $36M | — |
| 2012 | $767M | $406M | $65M | $40M | — |
| 2011 | $725M | $375M | $8M | $752,000 | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.33B | $1.29B | $1.03B | — | — |
| 2024 | $2.31B | $1.34B | $963M | — | — |
| 2023 | $2.30B | $1.47B | $834M | — | — |
| 2022 | $2.30B | $1.55B | $746M | — | — |
| 2021 | $1.77B | $981M | $785M | — | — |
| 2020 | $1.75B | $1.04B | $709M | — | — |
| 2019 | $1.78B | $1.06B | $710M | $26M | — |
| 2018 | $1.37B | $707M | $662M | $18M | $457M |
| 2017 | $1.36B | $727M | $631M | $33M | $486M |
| 2016 | $1.33B | $748M | $581M | $27M | $498M |
| 2015 | $1.10B | $517M | $585M | $73M | $271M |
| 2014 | $1.10B | $517M | $581M | $66M | $241M |
| 2013 | $1.09B | $484M | $606M | $54M | $216M |
| 2012 | $1.08B | $472M | $607M | $24M | $162M |
| 2011 | $936M | $363M | $573M | $26M | $144M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $171M | $20M | $151M |
| 2024 | $167M | $13M | $154M |
| 2023 | $125M | $19M | $106M |
| 2022 | $33M | $22M | $12M |
| 2021 | $112M | $15M | $97M |
| 2020 | $65M | $13M | $52M |
| 2019 | $95M | $20M | $75M |
| 2018 | $75M | $17M | $58M |
| 2017 | $66M | $13M | $53M |
| 2016 | $40M | $15M | $25M |
| 2015 | $51M | $15M | $36M |
| 2014 | $65M | $15M | $50M |
| 2013 | $81M | $18M | $63M |
| 2012 | $95M | $22M | $74M |
| 2011 | $103M | $18M | $85M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CNMD)